-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
There are abnormalities in the regulation of multiple innate and adaptive immune pathways in patients with systemic lupus erythematosus (SLE)
Immuno -Iberdomide is a novel oral cereblon E3 ubiquitin ligase immunomodulator that promotes proteasomal degradation of Ikaros and Aiolos
In the phase II clinical study, patients were randomized to receive either oral Iberdomide (0.
A total of 288 patients were enrolled in the study, of which 81 received Iberdomide at a dose of 0.
At 24 weeks, the proportion of patients who achieved an SRI-4 response was 54% in the iberdomide 0.
Phase II clinical studies have confirmed that iberdomide 0.
Iberdomide 0.
Original source:
Joan T.
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
Leave a comment here